Xiaolu Yang

Second Military Medical University — China

Medicine · Health Sciences

15h-index2.5kcitations47works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(20), Cancer Genomics and Diagnostics(8), Soil Carbon and Nitrogen Dynamics(5), Pancreatic and Hepatic Oncology Research(5), Plant Molecular Biology Research(4)

Publications46 total

Corrigendum to “The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post- neoadjuvant therapy” [Cancer Lett. (2026), Online ahead of print]
Cancer Letters·2026
The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy
Cancer Letters·2026
Investigating the molecular mechanisms and clinical potential of APO+ endothelial cells associated with PANoptosis in the tumor microenvironment of hepatocellular carcinoma using single-cell sequencing data
Translational Oncology·2025· 2 citedOpen Access
Camellia Nitidissima Exosome-Like Nanovesicles Exhibit Broad-Spectrum Antitumor Activity Via Lipid-Protein Synergy: Insights from Lipidomics and Proteomics
SSRN Electronic Journal·2025Open Access
CellREADR: An ADAR-based RNA sensor-actuator device
Methods in enzymology on CD-ROM/Methods in enzymology·2025· 3 cited
RNA programmable cell targeting and manipulation with CellREADR
2024Open Access
Detection and characterization of pancreatic and biliary tract cancers using cell-free DNA fragmentomics
Journal of Experimental & Clinical Cancer Research·2024· 11 citedOpen Access
Identification of molecular subtypes based on chromatin regulator-related genes and experimental verification of the role of ASCL1 in conferring chemotherapy resistance to breast cancer
Frontiers in Immunology·2024· 2 citedOpen Access
Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S3 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S4 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Data from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
Table S2 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Yige Wu(23), Michael C. Wendl(23), Matthew A. Wyczalkowski(23), Li Ding(22), Ruiyang Liu(22), Preet Lal(22), Hui Zhang(22), Kazuhito Sato(21), Chia-Kuei Mo(21), Andrew Shinkle(20), James J. Hsieh(20), John M. Herndon(19), Hua Sun(19), Sherri R. Davies(19), Ryan C. Fields(19), Feng Chen(19), Yanyan Zhao(18), R. Jay Mashl(18), Siqi Chen(17), Yuefan Wang(17)